However, even in animal models, as shown in the early studies by Allison’s group [9,10], it was not established the quantity and quality of TAAs targeted in mice in which regressions of the transplantable B16 melanoma or sarcomas after CTLA-4 blockade were observed. The gene discussed is CTLA4; the disease is sarcoma.